BTOG 2022 Summer Meeting | Managing epithelial mesothelioma

Riyaz Shah, BSc(Hons), MBBS, FRCP, PhD, Kent Oncology Centre, UK, discusses the management of epithelial mesothelioma. There has been a recent rise in the incidence rate of mesothelioma in relation to the levels of asbestos exposure that was prevalent 20-40 years ago. Dr Shah highlights the Phase III CHECKMATE-743 (NCT02899299) study exploring first-line immunotherapy with nivolumab and ipilimumab versus chemotherapy which demonstrated improved survival rates and quality of life with immunotherapy. This interview took place at the BTOG 2022 Summer Meeting congress in London.